Neurotech collaborates with world-renowned investigators, researchers, and organizations in ophthalmology. These collaborations allow Neurotech to access expertise from recognized leaders in ophthalmology, who provide valuable feedback regarding scientific research, product enhancements and clinical trial designs. Neurotech continues to explore new relationships in order to maintain a technological advantage in the field of retinal medicine. Significant research collaborations include:
The Lowy Medical Research Institute (LMRI)
Neurotech collaborates with Lowy Medical Research Institute, an innovative organization dedicated to both laboratory and clinical research of degenerative eye diseases, such as Macular Telangiectasia.
University of California, San Francisco
Researchers at UCSF are examining the effects of NT-501 Ciliary Neurotrophic Factor (CNTF) ECT in cone preservation as measured by Adaptive Optic Scanning Laser Ophthalmoscopy (AOSLO) in ongoing clinical trials.
Foundation Fighting Blindness
Neurotech has a long-standing relationship with the Foundation Fighting Blindness, one of the world’s leading charitable organizations dedicated to finding cures for diseases of the eye. The Foundation recognized the potential of Neurotech ECT as an intraocular therapeutic drug delivery technology for retinal diseases, provided critical funding for an initial preclinical proof of principle study and helped support recent clinical studies.
National Eye Institute (NEI)
The NEI committed substantial resources to early stages of clinical development by assuming investigational responsibility for the initial clinical evaluation of ECT-mediated delivery of Ciliary Neurotrophic Factor (CNTF) in patients with retinitis pigmentosa.
University of Miami/Bascom Palmer Eye Institute
Researchers at Bascom Palmer have provided valuable scientific research as well as clinical development support of ECT, CNTF and follow-on factors under development.
University of Pennsylvania
Researchers at University of Pennsylvania have provided valuable scientific research at the preclinical level in the development of ECT, CNTF and follow-on factors under development.
University of Zurich
Researchers at the University of Zurich have collaborated with Neurotech in evaluating the potential of ECT to deliver alternative scaffold – based peptide drugs.
Neurotech works closely with Covance Laboratories to evaluate the safety, toxicokinetics and characterization of VEGF inhibitor factors delivered by ECT.